广州麓鹏制药有限公司
Investors 2
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | Lake Bleu ... | lakebleu-c... |
Mentions in press and media 1
| Date | Title | Description |
| 21.05.2026 | Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL | Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations GUANGZHOU, China and SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Lupeng ... |